Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12394760 | 0.88 | ALOX5 (0.35) | ALOX5 | |
| SCHEMBL827337 | 0.82 | ALOX5 (0.55) | ALOX5 | |
| SCHEMBL16213682 | 0.74 | NPC1 (0.36) | ALOX5 | |
| SCHEMBL9967682 | 0.72 | CHRM2 (0.37) | ALOX5 | |
| SCHEMBL9967681 | 0.70 | ALDH1A1 (0.43) | ALOX5 | |
| SCHEMBL17929805 | 0.70 | ALOX5 (0.30) | ALOX5 | |
| SCHEMBL8224692 | 0.70 | CYP2A6 (0.42) | ALOX5 | |
| SCHEMBL31498244 | 0.69 | HIF1A (0.49) | ALOX5HIF1AEPAS1LMNA | |
| SCHEMBL31498245 | 0.69 | HIF1A (0.49) | ALOX5HIF1AEPAS1LMNA | |
| SCHEMBL14378129 | 0.69 | ALDH1A1 (0.53) | ALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2009073432-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | TUBB6, TUBB3, TUBB2A | ALOX5 36/4885FNTA 181/4885PGGT1B 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.